Fernando Eduardo Ezquer Romero
Full Professor
Universidad del Desarrollo
Santiago, Chile
Regenerative Medicine, Mesenchymal Stem Cells, Induced Pluripotent Stem Cells, Animal Models, Diabetes Mellitus, Alcoholism, Addictions
-
Cell Biology, Molecular Biology and Neuroscience, UNIVERSIDAD DE CHILE. Chile, 2006
-
Molecular Biologist, Universidad Nacional de San Luis. Argentina, 2001
-
Associate Professor Full Time
Universidad del Desarrollo
Medicine
Santiago, Chile
2006 - 2020
-
Full Professor Full Time
Universidad del Desarrollo
Medicine
Santiago, Chile
2020 - A la fecha
-
Vice-Director Center for Regenerative Medicine Full Time
Universidad del Desarrollo
Santiago, Chile
2016 - A la fecha
Human Capital Training
Undergraduate Thesis
Karla Leal Villegas, Biotecnology, Faculty of Agricultural and Forestry Sciences, Universidad de la Frontera. Finished 2014 (Role: Director)
Scarlet Montecino Villalobos, Biochemist, Faculty of Sciences, Pontificia Universidad Catolica de Valparaiso. Finished 2015 (Role: Director)
Katheryne Gonzalez Bravo, Medical Technology, Universidad Pedro de Valdivia. Finished 2018 (Role: Director)
Diego Díaz Gomez, Biochemist, Faculty of Sciences, Pontifícia Universidad Católica de Valparaiso. Finished 2019 (Role: Director)
María Constanza Cárcamo Aguilera, Biochemist, Faculty of Chemical and Pharmaceutical Sciences, Universidad de Chile. Finished 2020 (Role: Director)
Esteban Ariel Rodríguez Sanhueza, Biochemist, Faculty of Chemical and Pharmaceutical Sciences, Universidad de Chile. Finished 2021 (Role: Director)
Carolina Ponce, Biotecnology, Faculty of Agricultural and Forestry Sciences, Universidad de la Frontera. Finished 2021 (Role: Director)
Master Thesis
Martina Redel Villaroel. Master in Neuroscience. Faculty of Medicine. Universidad de Chile. Finished 2021. (Role: Co-Director).
PhD Thesis
Andrea Tapia Bustos, PhD in Pharmacology, Faculty of Chemical and Pharmaceutical Sciences, Universidad de Chile. Finished 2020 (Role: Co-Director)
José Luis Ordoñes Belmar, PhD in Pharmaceutical Sciences, Faculty of Chemical and Pharmaceutical Sciences, Universidad de Chile. Under developing (Role: Co-Director)
Alba Avila. PhD in Science and Innovation in Medicine, Faculty of Medicine Clínica Alemana-Universidad del Desarrollo. Under developiung (Role: Director).
Mauricio Quezada Diez. PhD in Science and Innovation in Medicine, Faculty of Medicine Clínica Alemana-Universidad del Desarrollo. Under developing (Role: Director).
Marta Catalina Zamorano Cataldo. PhD in Pharmacology. Faculty of Medicine. Universidad del Desarrollo. Under developing (Role: Co-Director).
Invention patents associated with Biopharmaceuticals
Ezquer M, Ezquer F. Pattent Application N°201502971 (5/10/2015). Biopharmacological composition that comprises components produced and / or secreted by mesenchymal stem cells (MSC) that allow to recover the tissue regenerative capacity, in a situation of hepatic steatosis or where the endogenous regenerative capacity of the liver tissue is inhibited.
Ezquer F, Israel Y, Ezquer M, Quintanilla ME, Morales P, Herrera-Marschitz M. Pattent Application Nº 201700237 (27/01/2017). Injectable or intranasal composition comprising unstimulated or preconditioned mesenchymal stem cells (MSC), culture media derived from preconditioned MSC or exosomes derived from their culture and excipients; and its use to reduce drug use or block relapse due to deprivation, in a person with addiction.
Ezquer F, Israel Y, Ezquer M, Quintanilla ME, Morales P, Herrera-Marschitz M,. Pattent Application Nº PCT/CL2018/050063 (3/08/2018). Pharmaceutical composition for the treatment of addiction to psychoactive substances and / or for the prevention of relapses to said addiction
Clinical Studies
Autores: Mizón C, Conget P, Ezquer F, Ezquer M. Administración intravenosa de células madre mesenquimáticas alogénicas contribuyen al tratamiento de pacientes con diabetes mellitus tipo 1. Clínica Alemana de Santiago (2015-2018).
Stem cells for the treatment of patients with type 1 diabetes mellitus |
Development of Novel Therapeutic Alternatives for Alcohol-Use Disorders: A Multidisciplinary Approach |
Acute on chronic liver failure: reversion by systemic administration of 3D spheroids-derived mesenchymal stem cells |
Opioid addiction and associated cognitive damage: Inhibition by intranasal mesenchymal stem cell secretome administration |
MESENCHYMAL STEM CELLS-SECRETOME PROVIDES PROTECTION IN NEONATAL HYPOXIA-REOXYGENATION. MECHANISMS AND TRANSLATIONAL STUDIES |
THE OXIDATIVE STRESS-NEUROINFLAMMATION SYNERGY=> ROLE IN THE PERPETUATION OF ALCOHOL INTAKE AND THERAPEUTIC AVENUES |
INTERNATIONAL RESEARCH NETWORK FOR THE DEVELOPMENT OF INDUCED PLURIPOTENT STEM CELL TECHNOLOGY |
TREATING THE WHOLE NOT THE HOLE=> ADMINISTRATION OF ACELLULAR DERIVATIVE FROM MESENCHYMAL STEM CELLS SUBJECTED TO A PRECONDITIONING STIMULUS REVERTS DIABETIC NEUROPATHY AND PREVENTS DIABETIC FOOT ULCERS |
EVALUATION OF THE THERAPEUTIC EFFECT OF MESENCHYMAL STEM CELL -ACELULAR DERIVATE- ON DRUG INDUCED STEATOSIS, IN A MODEL OF NORMAL AND IMPAIRED LIVER REGENERATION CAPACITY |
DONOR MULTIPOTENT MESENCHYMAL STROMAL CELLS MODIFY THE NATURAL EVOLUTION OF RETINAL DAMAGE IN DIABETIC MICE |
THE ETIOLOGY OF DIABETES AND/OR THE STAGE OF DIABETIC NEPHROPATHY MODIFY THE RENOPROTECTIVE EFFECT OF DONOR MULTIPOTENT MESENCHYMAL STROMAL CELLS? |
IDENTIFICATION OF CELLULAR AND MOLECULAR MECHANISMS BEHIND BETA-PANCREATIC ISLETS REGENERATION INDUCED BY MULTIPOTENT MESENCHYMAL STROMAL CELLS ADMINISTRATION INTO TYPE 1 DIABETIC MICE. |
IDENTIFICACION DE EPITOPES INMUNODOMINANTES INVOLUCRADOS EN LA RESPUESTA INMUNE CELULAR CONTRA HANTAVIRUS ANDES Y CARACTERIZACION DE LOS LINFOCITOS T RESPONSABLES=> BASE PARA EL DESARROLLO DE UNA VACUNA. |